{"id":30069,"date":"2024-10-16T16:47:33","date_gmt":"2024-10-16T11:17:33","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=30069"},"modified":"2024-10-16T17:33:36","modified_gmt":"2024-10-16T12:03:36","slug":"pompe-disease-commercial-activities","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/pompe-disease-commercial-activities","title":{"rendered":"Transforming Pompe Disease Care: Latest Innovations and Strategic Advances in Treatment"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-69ddf6b439578\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-69ddf6b439578\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/pompe-disease-commercial-activities\/#Current_Commercial_Strategies_and_Innovations_in_Pompe_Disease_Treatment\" >Current Commercial Strategies and Innovations in Pompe Disease Treatment<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/pompe-disease-commercial-activities\/#September_2024\" >September 2024<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/pompe-disease-commercial-activities\/#July_2024\" >July 2024<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/pompe-disease-commercial-activities\/#June_2024\" >June 2024<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/pompe-disease-commercial-activities\/#May_2024\" >May 2024<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/www.delveinsight.com\/blog\/pompe-disease-commercial-activities\/#April_2024\" >April 2024<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/www.delveinsight.com\/blog\/pompe-disease-commercial-activities\/#December_2023\" >December 2023<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/www.delveinsight.com\/blog\/pompe-disease-commercial-activities\/#September_2023\" >September 2023<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/www.delveinsight.com\/blog\/pompe-disease-commercial-activities\/#Conclusion\" >Conclusion<\/a><\/li><\/ul><\/nav><\/div>\n\n<p><strong>Pompe disease<\/strong> is a rare genetic disorder that presents a spectrum of severity, with varying rates of progression and ages of onset. Symptoms can appear anywhere from infancy to late adulthood, with earlier onset generally associated with more rapid progression and increased severity. At all ages, the disease is marked by <strong>skeletal muscle weakness<\/strong>, leading to mobility issues and respiratory complications. <a href=\"https:\/\/www.delveinsight.com\/report-store\/pompe-disease-epidemiology-forecast\"><strong>Pompe disease prevalence<\/strong><\/a> spans different ethnic groups worldwide, with an incidence rate of approximately 1 in 40,000 births in the United States and the Netherlands. According to DelveInsight, there were about 13,000 total prevalent cases of Pompe disease in 2023, with the EU4 and the UK accounting for 25% of these cases. In the United States alone, an estimated 8,600 people were diagnosed with Pompe disease in 2023, with 98% of cases occurring in adults. Notably, around 80% of infantile-onset Pompe disease cases were CRIM-positive, a phenotype characterized by some residual enzyme activity that can affect disease progression and response to treatment.<\/p>\n\n\n\n<p><em><strong>Get a full understanding of <a href=\"https:\/\/www.delveinsight.com\/blog\/pompe-disease-emerging-therapies\" class=\"ek-link\">Pompe disease<\/a><\/strong><\/em><\/p>\n\n\n\n<p>Several <a href=\"https:\/\/www.delveinsight.com\/report-store\/pompe-disease-pipeline-insight\">Pompe disease therapies<\/a> are currently approved to manage the condition. <strong>MYOZYME (alglucosidase alfa)<\/strong>, developed by Genzyme\/Sanofi, was the first <strong>Pompe disease drug<\/strong> to receive FDA approval in 2006 for treating infantile-onset Pompe disease (IOPD). Similarly, <strong>LUMIZYME (alglucosidase alfa)<\/strong>, also from Genzyme\/Sanofi, was approved in 2010 to treat late-onset Pompe disease (LOPD) in patients over eight years old, offering an exogenous source of GAA to combat glycogen buildup. In the realm of emerging Pompe disease therapies, <strong>ACTUS-101<\/strong> by Asklepios Biopharmaceutical is an innovative gene therapy aimed at correcting GAA deficiency through AAV technology, addressing the underlying cause of the disease. Additionally, <strong>Avalglucosidase alfa (Nexviazyme)<\/strong>, another Sanofi product, is a recombinant form of GAA designed to enhance glycogen digestion and absorption, offering a promising new <a href=\"https:\/\/www.delveinsight.com\/report-store\/pompe-disease-market\">Pompe disease treatment<\/a> for patients with LOPD.<\/p>\n\n\n\n<p><strong><em>To learn more about the treatment landscape of Pompe disease, click <\/em><\/strong><a href=\"https:\/\/www.delveinsight.com\/blog\/pompe-disease-treatment-market\"><strong><em>here <\/em><\/strong><\/a><strong><em>to read our latest blog&nbsp;<\/em><\/strong><\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-current-commercial-strategies-and-innovations-in-pompe-disease-treatment\"><span class=\"ez-toc-section\" id=\"Current_Commercial_Strategies_and_Innovations_in_Pompe_Disease_Treatment\"><\/span>Current Commercial Strategies and Innovations in Pompe Disease Treatment<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>While the search for a cure continues, advancements in Pompe disease drugs and therapies are evolving. The treatment landscape has seen significant developments over recent months, with new and emerging drugs reshaping the <a href=\"https:\/\/www.delveinsight.com\/blog\/pompe-disease-emerging-therapies\">Pompe disease market<\/a> and bringing hope to patients and their families.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-september-2024\"><span class=\"ez-toc-section\" id=\"September_2024\"><\/span>September 2024<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>A groundbreaking noninvasive imaging technique, <strong>multispectral optoacoustic tomography (MSOT)<\/strong>, was discovered to outperform standard methods like MRI and ultrasound in visualizing diseased muscles in individuals with late-onset Pompe disease. This technique uses light and sound waves to provide a detailed view of deeper muscle layers, offering a more precise way to monitor the condition. Researchers highlighted that the integration of MSOT imaging could reduce the need for invasive procedures, potentially transforming Pompe disease treatment approaches.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-july-2024\"><span class=\"ez-toc-section\" id=\"July_2024\"><\/span>July 2024<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>The <strong>Alabama Department of Public Health (ADPH)<\/strong> introduced <strong>Pompe disease<\/strong> and <strong>Mucopolysaccharidosis Type I (MPS I)<\/strong> into its newborn screening panel. This addition is expected to help in the early diagnosis of <strong>Pompe disease<\/strong> through a simple blood test, enabling timely interventions that can prevent the severe symptoms from manifesting. By catching the disease early, newborns have a better chance at normal development.<\/p>\n\n\n\n<p>A study conducted in Mexico revealed that Pompe disease patients carried GAA gene mutations associated with both infantile and adult-onset Pompe disease. This genetic diversity reflects the population\u2019s broad mutation spectrum, and researchers suggested that further studies are necessary to better characterize Pompe disease prevalence in Mexico.<\/p>\n\n\n\n<p>Meanwhile, <strong>Roche<\/strong> made headlines by discontinuing the development of its gene therapy <strong>SPK-3006<\/strong> for <strong>late-onset Pompe disease<\/strong>. Initially acquired through its 2019 purchase of Spark Therapeutics, the program was part of a larger effort to explore <a href=\"https:\/\/www.delveinsight.com\/report-store\/pompe-disease-pipeline-insight\">gene therapies for Pompe<\/a> and other genetic diseases. This decision follows a similar discontinuation of another Spark program in 2023, as Roche continues to evaluate its strategic focus.<\/p>\n\n\n\n<p>In another major move, <strong>Crosswalk Therapeutics<\/strong> acquired gene therapy compounds for <strong>Pompe disease<\/strong> and Fabry disease from Codexis. These compounds were initially part of a collaboration between Codexis and Takeda, which was discontinued as Takeda shifted away from early-stage AAV gene therapy research.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-june-2024\"><span class=\"ez-toc-section\" id=\"June_2024\"><\/span>June 2024<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>At the New Directions in Biology and Disease of Skeletal Muscle Conference, <strong>Dyne Therapeutics<\/strong> showcased preclinical data on its <strong>FORCE platform<\/strong>, which demonstrated the potential to deliver <strong>enzyme replacement therapy (ERT)<\/strong> directly to skeletal and cardiac muscles as well as the <strong>central nervous system (CNS)<\/strong>. This breakthrough represents a promising future for Pompe disease therapies that target multiple affected areas in the body.<\/p>\n\n\n\n<p><strong>Amicus Therapeutics<\/strong> earned the prestigious <strong>Prix Galien U.K. Award for Best Pharmaceutical Product<\/strong> for its two-component therapy, <strong>Pombiliti + Opfolda<\/strong>. This combination therapy is specifically designed for adults with late-onset Pompe disease (LOPD), offering an innovative approach for patients who haven\u2019t responded well to previous treatments.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-may-2024\"><span class=\"ez-toc-section\" id=\"May_2024\"><\/span>May 2024<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>In a major licensing deal, <strong>Shionogi &amp; Co., Ltd.<\/strong> secured the rights to <strong>MZE001<\/strong>, an oral <strong>glycogen synthase 1 (GYS1) inhibitor<\/strong> aimed at treating Pompe disease by limiting glycogen buildup. This agreement came on the heels of <strong>Sanofi\u2019s<\/strong> failed attempt to acquire the asset, following a <strong>Federal Trade Commission (FTC)<\/strong> ruling that blocked the deal on antitrust grounds. The FTC argued that the acquisition would have eliminated competition and preserved Sanofi\u2019s dominant position in the Pompe disease market.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-april-2024\"><span class=\"ez-toc-section\" id=\"April_2024\"><\/span>April 2024<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p><strong>Asklepios BioPharmaceutical<\/strong> continued evaluating its gene therapy, <strong>ACTUS-101<\/strong>, for <strong>late-onset Pompe disease (LOPD)<\/strong>. This <a href=\"https:\/\/www.delveinsight.com\/report-store\/pompe-disease-market\">Pompe disease therapy<\/a>, which aims to address <strong>GAA enzyme deficiency<\/strong>, has been under investigation since 2019. Although updates on the trial have been sparse, the therapy remains active and is not currently recruiting.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-december-2023\"><span class=\"ez-toc-section\" id=\"December_2023\"><\/span>December 2023<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>In late 2023, <strong>Sanofi<\/strong> made headlines by abandoning its proposed licensing deal with <strong>Maze Therapeutics<\/strong> after the <strong>FTC<\/strong> intervened, citing antitrust concerns. The agreement would have given Sanofi access to <strong>MZE001<\/strong>, Maze\u2019s investigational therapy targeting <strong>Pompe disease<\/strong>, but the FTC argued that the acquisition would hinder competition in the <strong>Pompe disease treatment<\/strong> space and prevent innovation. Sanofi\u2019s decision to walk away from the deal underscores the complexity of navigating the competitive <strong>Pompe disease drug<\/strong> landscape.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-september-2023\"><span class=\"ez-toc-section\" id=\"September_2023\"><\/span>September 2023<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>The <strong>FDA<\/strong> approved <strong>Amicus Therapeutics<\/strong> for its two-component therapy, <strong>POMBILITI (cipaglucosidase alfa-atga) + OPFOLDA (miglustat)<\/strong>, for adults with <strong>late-onset Pompe disease (LOPD)<\/strong>. This approval marked a major milestone for Amicus, offering a new option for patients who have not responded adequately to existing <strong>ERT<\/strong>. <strong>Pompe disease therapies<\/strong> continue to evolve, and this two-component approach represents a significant advancement for the Pompe disease market.<\/p>\n\n\n\n<p><strong><em>Read more on the <a href=\"https:\/\/www.delveinsight.com\/blog\/pompe-disease-emerging-markets\" class=\"ek-link\">Pompe disease emerging drugs landscape<\/a>\u00a0<\/em><\/strong><\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-conclusion\"><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span>Conclusion<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The journey of <strong>Pompe disease therapies<\/strong> has been nothing short of transformative, with constant breakthroughs and scientific discoveries shaping the horizon. From the development of enzyme replacement therapies like <strong>MYOZYME<\/strong> and <strong>LUMIZYME<\/strong> to emerging gene therapies such as <strong>ACTUS-101<\/strong> and the innovative two-component therapy, <strong>POMBILITI + OPFOLDA<\/strong>, the medical community has been relentless in its quest to combat this rare disease. As the competition among pharmaceutical giants intensifies and new technologies like <strong>MSOT imaging<\/strong> emerge, the future holds incredible promise for those affected by <strong>Pompe disease<\/strong>. The recent regulatory and commercial activities underscore a <a href=\"https:\/\/www.delveinsight.com\/report-store\/pompe-disease-market\">new era in Pompe disease treatment<\/a>\u2014a time where early diagnosis, personalized gene therapies, and global collaborations are redefining the standard of care. For patients and families, these advancements fuel the hope that tomorrow\u2019s Pompe disease therapies will offer a longer, healthier future.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><a href=\"https:\/\/www.delveinsight.com\/report-store\/pompe-disease-market\"><img decoding=\"async\" width=\"1024\" height=\"194\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/09\/30145146\/Pompe-Disease-Market-Outlook-1024x194.png\" alt=\"\" class=\"wp-image-29803\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/09\/30145146\/Pompe-Disease-Market-Outlook-1024x194.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/09\/30145146\/Pompe-Disease-Market-Outlook-300x57.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/09\/30145146\/Pompe-Disease-Market-Outlook-150x28.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/09\/30145146\/Pompe-Disease-Market-Outlook-768x145.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/09\/30145146\/Pompe-Disease-Market-Outlook-1536x291.png 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/09\/30145146\/Pompe-Disease-Market-Outlook.png 1584w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/a><\/figure>\n","protected":false},"excerpt":{"rendered":"<p>Pompe disease is a rare genetic disorder that presents a spectrum of severity, with varying rates of progression and ages of onset. Symptoms can appear anywhere from infancy to late adulthood, with earlier onset generally associated with more rapid progression and increased severity. At all ages, the disease is marked by skeletal muscle weakness, leading [&hellip;]<\/p>\n","protected":false},"author":20,"featured_media":30071,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[204,704,489,4640,4540,4556,4541,502,17267],"industry":[17225],"therapeutic_areas":[17238,17234],"class_list":["post-30069","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","tag-delveinsight","tag-fda","tag-pompe-disease","tag-pompe-disease-emerging-markets","tag-pompe-disease-market","tag-pompe-disease-pipeline","tag-pompe-disease-therapy-market","tag-rare-disease","tag-rare-genetic","industry-pharmaceutical","therapeutic_areas-genetic-disorders","therapeutic_areas-rare-diseases"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Pompe Disease: Commercial Strategies for Emerging Therapies<\/title>\n<meta name=\"description\" content=\"Explore the evolving landscape of Pompe disease treatments and recent advancements impacting patient care.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/pompe-disease-commercial-activities\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pompe Disease: Commercial Strategies for Emerging Therapies\" \/>\n<meta property=\"og:description\" content=\"Explore the evolving landscape of Pompe disease treatments and recent advancements impacting patient care.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/pompe-disease-commercial-activities\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2024-10-16T11:17:33+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-10-16T12:03:36+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/10\/16162932\/Feature-Transforming-Pompe-Disease-Care_-Pioneering-Innovations-and-Strategic-Advances-in-Treatment.png\" \/>\n\t<meta property=\"og:image:width\" content=\"466\" \/>\n\t<meta property=\"og:image:height\" content=\"284\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Jatin Vimal\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Jatin Vimal\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Pompe Disease: Commercial Strategies for Emerging Therapies","description":"Explore the evolving landscape of Pompe disease treatments and recent advancements impacting patient care.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/pompe-disease-commercial-activities","og_locale":"en_US","og_type":"article","og_title":"Pompe Disease: Commercial Strategies for Emerging Therapies","og_description":"Explore the evolving landscape of Pompe disease treatments and recent advancements impacting patient care.","og_url":"https:\/\/www.delveinsight.com\/blog\/pompe-disease-commercial-activities","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2024-10-16T11:17:33+00:00","article_modified_time":"2024-10-16T12:03:36+00:00","og_image":[{"width":466,"height":284,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/10\/16162932\/Feature-Transforming-Pompe-Disease-Care_-Pioneering-Innovations-and-Strategic-Advances-in-Treatment.png","type":"image\/png"}],"author":"Jatin Vimal","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Jatin Vimal","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/pompe-disease-commercial-activities","url":"https:\/\/www.delveinsight.com\/blog\/pompe-disease-commercial-activities","name":"Pompe Disease: Commercial Strategies for Emerging Therapies","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/pompe-disease-commercial-activities#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/pompe-disease-commercial-activities#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/10\/16162932\/Feature-Transforming-Pompe-Disease-Care_-Pioneering-Innovations-and-Strategic-Advances-in-Treatment.png","datePublished":"2024-10-16T11:17:33+00:00","dateModified":"2024-10-16T12:03:36+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/c846f0323e948c55336d657b654f3158"},"description":"Explore the evolving landscape of Pompe disease treatments and recent advancements impacting patient care.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/pompe-disease-commercial-activities"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/pompe-disease-commercial-activities#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/10\/16162932\/Feature-Transforming-Pompe-Disease-Care_-Pioneering-Innovations-and-Strategic-Advances-in-Treatment.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/10\/16162932\/Feature-Transforming-Pompe-Disease-Care_-Pioneering-Innovations-and-Strategic-Advances-in-Treatment.png","width":466,"height":284,"caption":"Feature-Transforming Pompe Disease Care_ Pioneering Innovations and Strategic Advances in Treatment"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/c846f0323e948c55336d657b654f3158","name":"Jatin Vimal","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/10dcf4b5071c366691525fa20af33b87e8a3897e6d0acc1a2b09a7b99b8d8ae1?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/10dcf4b5071c366691525fa20af33b87e8a3897e6d0acc1a2b09a7b99b8d8ae1?s=96&d=mm&r=g","caption":"Jatin Vimal"},"sameAs":["https:\/\/www.delveinsight.com"]}]}},"author_meta":{"display_name":"Jatin Vimal","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/jatin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/10\/16162932\/Feature-Transforming-Pompe-Disease-Care_-Pioneering-Innovations-and-Strategic-Advances-in-Treatment-300x183.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">DelveInsight<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">FDA<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Pompe Disease<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Pompe disease Emerging markets<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Pompe disease market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Pompe Disease Pipeline<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Pompe disease therapy market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Rare Disease<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Rare Genetic<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">DelveInsight<\/span>","<span class=\"advgb-post-tax-term\">FDA<\/span>","<span class=\"advgb-post-tax-term\">Pompe Disease<\/span>","<span class=\"advgb-post-tax-term\">Pompe disease Emerging markets<\/span>","<span class=\"advgb-post-tax-term\">Pompe disease market<\/span>","<span class=\"advgb-post-tax-term\">Pompe Disease Pipeline<\/span>","<span class=\"advgb-post-tax-term\">Pompe disease therapy market<\/span>","<span class=\"advgb-post-tax-term\">Rare Disease<\/span>","<span class=\"advgb-post-tax-term\">Rare Genetic<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 1 year ago","modified":"Updated 1 year ago"},"absolute_dates":{"created":"Posted on Oct 16, 2024","modified":"Updated on Oct 16, 2024"},"absolute_dates_time":{"created":"Posted on Oct 16, 2024 4:47 pm","modified":"Updated on Oct 16, 2024 5:33 pm"},"featured_img_caption":"Feature-Transforming Pompe Disease Care_ Pioneering Innovations and Strategic Advances in Treatment","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/30069","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/20"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=30069"}],"version-history":[{"count":3,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/30069\/revisions"}],"predecessor-version":[{"id":30075,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/30069\/revisions\/30075"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/30071"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=30069"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=30069"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=30069"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=30069"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=30069"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}